Home » Stocks » Kura Oncology

Kura Oncology, Inc. (KURA)

Stock Price: $33.13 USD -0.98 (-2.87%)
Updated Oct 19, 2020 3:22 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.86B
Revenue (ttm) n/a
Net Income (ttm) -73.95M
Shares Out 56.28M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $33.13
Previous Close $34.11
Change ($) -0.98
Change (%) -2.87%
Day's Open 34.07
Day's Range 33.04 - 35.02
Day's Volume 317,697
52-Week Range 6.35 - 35.25

More Stats

Market Cap 1.86B
Enterprise Value 1.54B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.28M
Float 50.82M
EPS (basic) -1.58
EPS (diluted) -1.58
FCF / Share -1.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.00M
Short Ratio 3.88
Short % of Float 5.89%
Beta 2.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.98
Revenue n/a
Operating Income -78.16M
Net Income -73.95M
Free Cash Flow -61.87M
Net Cash 325.56M
Net Cash / Share 5.78
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -15.76%
ROE -26.00%
ROIC -36.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-7.94% downside)
Current: $33.13
Target: 30.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-67.48-62.88-36.08-24.54-19.99
Net Income-63.14-60.45-35.43-27.56-22.63
Shares Outstanding41.9535.1923.2418.709.93
Earnings Per Share-1.51-1.72-1.52-1.47-2.28
Operating Cash Flow-54.76-48.66-28.44-25.35-17.93
Capital Expenditures-----0.06
Free Cash Flow-54.76-48.66-28.44-25.35-17.99
Cash & Equivalents23717993.1567.7985.75
Total Debt7.507.507.107.32-
Net Cash / Debt22917186.0560.4785.75
Book Value21916179.8756.8882.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kura Oncology, Inc.
Country United States
Employees 71
CEO Troy E. Wilson

Stock Information

Ticker Symbol KURA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KURA


Kura Oncology, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.